Pioneering brain and mind clinic Re:Cognition Health has announced the expansion of its highly successful international clinical trials services for Alzheimer’s disease and other related cognitive conditions into the USA. The launch comes in response to the overwhelming success of the practice in the UK and high demand for such medical facilities and services.
The new centre, located in Fairfax, Virginia on Arlington Boulevard, will provide access to the very best healthcare and treatment options for people living with, or at risk of developing Alzheimer’s disease and other causes of memory impairment leading to dementia.
Re:Cognition Health is a leading centre for international final phase clinical trials, changing the future for those with memory loss and other symptoms of cognitive impairment. Under the leadership of CEO and Medical Director Dr Emer MacSweeney, Re:Cognition Health will continue to pave the way for a future without Alzheimer’s disease with the continued expansion plans in the USA and beyond.
With over 140,000 people living with a diagnosis of mild cognitive impairment (MCI) or dementia in Virginia, Re:Cognition Health aims to support individuals with memory loss and other symptoms of cognitive impairment through providing education, clinical excellence and access to the most advanced treatments available worldwide. It is anticipated that the number of people with Alzheimer’s Disease will increase by 35.7% between now and 2025. Today, someone in the USA develops Alzheimer’s Disease every 67 seconds, by 2050 it’s expected to be every 33 seconds, according to the Alzheimer’s Association.
Dr. James Bicksel, who will lead the clinical trial team, has worked with prior clinical trials in the area and has been involved in improving memory care within the INOVA Health Care System and the Alzheimer’s Association, national Capital Area chapter.
Clinical trials are essential for advancing our understanding of medicine and improving the healthcare and quality of life for everyone affected by dementia and cognitive impairment. By participating in an international clinical study, individuals can gain the potential personal benefit of early access to a new generation treatment, whilst also having an important global impact on our ability to treat a given condition. All medical costs are covered by the pharmaceutical company, so the very best care and medical facilities are provided to the individual at no charge.
Dr MacSweeney comments, “We are delighted to be expanding our Re:Cognition Health centres into the USA, giving the opportunity for more people to gain access to the most advanced treatments available, worldwide. We look forward to offering patients the very best care and access to new emerging treatments.”
Dr Bicksel adds, “Opening a new clinical for clinical studies for Alzheimer’s Disease is a very positive step for the future in fighting this disease. Our patients will have the opportunity to be involved in clinical trials of the next generation of emerging medications whilst receiving outstanding medical care by a team of cognitive experts. We are very much looking forward to making a difference to the lives of people in Virginia and Washington DC.”